Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection

Acta Paediatrica, International Journal of Paediatrics

Volumn 100, Issue 3, 2011, Pages 324-329

  Pons, J M V ^a,b   Tebe C ^a,b   Paladio, N ^a,b   Garcia Altes, A ^b,c,d   Danes I ^e   Valls I Soler, A ^f  

^a Catalan Agency for Health Technology Assessment and Research   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

^d AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Bronchiolitis; Meta analysis; Palivizumab Respiratory Syncytial Virus; Passive immunoprophylaxis

Indexed keywords

HYPERIMMUNE GLOBULIN; MOTAVIZUMAB; PALIVIZUMAB;

ARTIFICIAL VENTILATION; CHILD CARE; CONGENITAL HEART DISEASE; CYANOTIC HEART DISEASE; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION RISK; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PASSIVE IMMUNIZATION; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNIZATION, PASSIVE; INFANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 79551594184     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2010.02059.x     Document Type: Review

References (38)

1. Bush A, Thomson AH,. Acute bronchiolitis. BMJ 2007; 335: 1037-41.
2. Smyth RL, Openshaw PJ,. Bronchiolitis. Lancet 2006; 368: 312-22.
3. Polack FP, Karron RA,. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 2004; 23 (1 Suppl): S65-73.
4. Sharland M, Bedford-Russell A,. Preventing respiratory syncitial virus bronchiolitis. BMJ 2001; 322: 62-3.
5. Groothuis JR, Nishida H,. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 2002; 44: 235-41.
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
7. Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 1999; 180: 35-40.
8. Storey S,. Respiratory syncytial virus market. Nat Rev Drug Discov 2010; 9: 15-6.
9. Carbonell-Estrany X, Simoes EA, Dagan R, Hall CB, Harris B, Hultquist M, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125: e35-51. doi:.
10. Morris SK, Dzolganovski B, Beyene J, Sung L,. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009; 9: 106. doi:.
11. Center for Drug Evaluation and Research (CDER). Palivizumab Product Approval Information-Licensing Action. Clinical review. Palivizumab (BLA number 97-1359). Annotated clinical review of biological license application [monograph on the Internet]. Rockville (USA): US Food and Drug Administration (FDA); 1998 [cited December 2007]. Available from http://www.fda.gov/cder/biologics/review/ palimed061998r2.pdf.
12. Center for Drug Evaluation and Research (CDER). Palivizumab Product Approval Information-Licensing Action. Statistical review [monograph on the Internet]. Rockville (USA): US Food and Drug Administration (FDA); 1998 [cited December 2007]. Available from http://www.fda.gov/cder/biologics/review/ palimed061998r6.pdf.
13. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
14. The Cochrane Collaboration. Review Manager (Rev man)[Computer program] Version 5.0. Copenhagen: the Nordi Cochrane Centre, The Cochrane Collaboration, 2008.
15. Management of Bronchiolitis in Infants and Children. Evidence Report/Technology Assessment Number 69. Agency for Healthcare Research and Quality Pub. No. 03-E009. U.S. Department of Health and Human Services, January 2003.
16. Black CP,. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003; 48: 209-33.
17. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A,. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1-86.
18. Wang EE, Tang NK,. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev 2006, issue 3. Art. No.:CD001725. doi:10.1002/14651858.CD001725.pub2.
19. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodríguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329: 1524-30.
20. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93-9.
21. Simoes EA, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998; 133: 492-9.
22. Lozano J, Escovar C, Vásquez V,. Monoclonal antibodies for preventing respiratory syncytial virus infection (Protocol). Cochrane Database Syst Rev 2007, Issue 3. Art. No.: CD006602. doi: 10.1002/14651858.CD006602. (Pubitemid 351805578)
23. Subramanian S, Weisman LE, Rhodes T, Ariagno R, Sánchez PL, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 1998; 17: 110-5. (Pubitemid 28096007)
24. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-40.
25. Avins AL,. Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics 1998; 24: 401-8.
26. Dumville JC, Hahn S, Miles JN, Torgerson DJ,. The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 2006; 27: 1-12.
27. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ,. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110: e53.
28. Mohan AK, Braun MM, Ellenberg S, Hedje J, Cote TR,. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infect Dis J 2004; 23: 342-5.
29. Moore T, Weiss S, Blaisdell C,. Reported fatal and serious adverse events associated with palivizumab [oral communication]. Baltimore, Maryland (US): Pediatric Academic Societies' Annual Meeting, 2002.
30. Egger M, Smith GD, Phillips AN,. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-7.
31. McConnochie KM, Roghmann KJ, Liptak GS,. Hospitalization for lower respiratory tract illness in infants: variation in rates among counties in New York State and areas within Monroe County. J Pediatr 1995; 126: 220-9.
32. Willson DF, Horn SD, Hendley JO, Smout R, Gassaway J,. Effect of practice variation on resource utilization in infants hospitalized for viral lower respiratory illness. Pediatrics 2001; 108: 851-5.
33. Johnson DW, Adair C, Brant R, Holmwood J, Mitchell I,. Differences in admission rates of children with bronchiolitis by pediatric and general emergency departments. Pediatrics 2002; 110: e49.
34. Mallory MD, Shay DK, Garrett J, Bordley WC,. Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics 2003; 111: e45-51.
35. Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connors EM, et al. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J 2009; 28: 835-7.
36. Temple R, Ellenberg SS,. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000; 133: 455-63.
37. Figueras-Aloy J, Quero J,. Recomendaciones para la prevenciõn de la infecciõn por virus respiratorio sincitial. An Pediatr (Barc) 2005; 63: 357-62.
38. Committee on Infectious Diseases. Policy statement-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.